US clinical-stage biopharma Nurix Therapeutics (Nasdaq: NRIX) saw its shares rise almost 11% to $9.19 yesterday morning, after it announced a multi-year, multi-target strategic collaboration agreement with Seagen (Nasdaq: SEGN) to advance a new class of medicines called degrader-antibody conjugates (DACs) for use in cancer.
The collaboration will focus on an innovative approach to combine two powerful technologies to target cancer - antibody-drug conjugation (ADC) and targeted protein degradation (TPD) - with the goal of creating drugs with new mechanisms of action as well as improved specificity and anti-cancer activity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze